Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKETprogram and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase
/PRNewswire/ Enterome, a clinical stage company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform,.